Send me real-time posts from this site at my email

Watchlist Update: 8-26 - HZNP - Horizon Pharma - Analyst Comments

TIGER'S TAKE:  On our watch list/trading list. This is a good longer-term biotech buy, also good for playing/trading dips and peaks.   $HZNP

Horizon Pharma risk/reward 'highly attractive,' says Piper Jaffray

After conducting a survey of 27 physicians who manage significant numbers of patients with thyroid eye disease, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $33 price target. The analyst says the survey reinforced his belief that teprotumumab will over time emerge as a go-to option in a broad swath of moderate-to-severe TED patients. He continues to view Horizon as one of the most attractive longer-term EBITDA growth stories in the broader biopharma space. Amsellem sees a "highly attractive" risk/reward profile at current share levels.

Source: (

$HZNP, Horizon Therapeutics Public Limited Company / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue